Departments of Medicine, University of Eastern Finland and Kuopio University Hospital, Kuopio, Finland.
Department of Experimental Vascular Medicine, Amsterdam UMC, Location AMC at University of Amsterdam, Amsterdam, The Netherlands.
Liver Int. 2021 Nov;41(11):2590-2600. doi: 10.1111/liv.15004. Epub 2021 Jul 14.
BACKGROUND & AIMS: Non-alcoholic fatty liver disease (NAFLD) increases morbidity and mortality. However, patients in biopsy-based cohorts are highly selected and the absolute risks of liver- and non-liver outcomes in NAFLD in population remains undefined. We analysed both liver-related and non-liver-related outcomes in Finnish population cohorts of NAFLD.
We included 10 993 individuals (6707 men, mean age 53.3 ± 12.6 years) with NAFLD (fatty liver index ≥60) from the Finnish population-based FINRISK and Health 2000 studies. Liver fibrosis was assessed by the dAAR score, and genetic risk by a recent polygenic risk score (PRS-5). Incident liver-related outcomes, cardiovascular disease (CVD), cancer and chronic kidney disease (CKD) were identified through linkage with national registries.
Mean follow-up was 12.1 years (1128 069 person-years). The crude incidence rate of liver-related outcomes in NAFLD was 0.97/1000 person-years. The cumulative incidence increased with age, being respectively 2.4% and 1.5% at 20 years in men and women aged 60 years at baseline, while the relative risks for CVD and cancer were 9-16 times higher. The risk of CKD exceeded that of liver outcomes at a baseline age around 50 years. 20-year cumulative incidence of liver-related outcomes was 4.3% in the high, and 1.5% in the low PRS-5 group. The dAAR score associated with liver outcomes, but not with extra-hepatic outcomes.
The absolute risk of liver-related outcomes in NAFLD is low, with much higher risk of CVD and cancer, emphasizing the need for more individualized and holistic risk-stratification in NAFLD.
非酒精性脂肪性肝病(NAFLD)会增加发病率和死亡率。然而,基于肝活检的队列患者筛选程度较高,NAFLD 患者的肝内和肝外结局的绝对风险仍不明确。本研究分析了芬兰 NAFLD 人群队列的肝相关和非肝相关结局。
我们纳入了来自芬兰人群基础 FINRISK 和 Health 2000 研究的 10993 名(6707 名男性,平均年龄 53.3±12.6 岁)NAFLD 患者(脂肪肝指数≥60)。通过 dAAR 评分评估肝纤维化,通过最近的多基因风险评分(PRS-5)评估遗传风险。通过与国家登记处的链接,确定新发的肝相关结局、心血管疾病(CVD)、癌症和慢性肾脏病(CKD)。
平均随访时间为 12.1 年(1128069 人年)。NAFLD 的肝相关结局粗发生率为 0.97/1000 人年。累积发病率随年龄增加而增加,在基线时年龄为 60 岁的男性和女性中,20 年时分别为 2.4%和 1.5%,而 CVD 和癌症的相对风险高 9-16 倍。在基线年龄约为 50 岁时,CKD 的风险超过了肝相关结局。高 PRS-5 组和低 PRS-5 组 20 年肝相关结局的累积发生率分别为 4.3%和 1.5%。dAAR 评分与肝结局相关,但与肝外结局无关。
NAFLD 患者的肝相关结局的绝对风险较低,但 CVD 和癌症的风险更高,这强调了需要对 NAFLD 进行更个体化和全面的风险分层。